VIGL — Vigil Neuroscience Balance Sheet
0.000.00%
- $128.35m
- $30.55m
- 10
- 18
- 38
- 10
Annual balance sheet for Vigil Neuroscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 24.2 | 91.4 | 187 | 118 | 97.8 |
Prepaid Expenses | |||||
Total Current Assets | 25.3 | 97.5 | 198 | 122 | 101 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0 | 1.27 | 1.4 | 17.9 | 16.1 |
Other Long Term Assets | |||||
Total Assets | 25.3 | 102 | 200 | 141 | 118 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2 | 9.88 | 11.3 | 11.7 | 34.1 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 6.54 | 9.95 | 11.3 | 24.6 | 46.1 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 18.8 | 92.5 | 189 | 116 | 71.6 |
Total Liabilities & Shareholders' Equity | 25.3 | 102 | 200 | 141 | 118 |
Total Common Shares Outstanding |